Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbetocin vs Oxytocin for PPH Prevention in High-Risk Cesarean Delivery
NCT06333340Recruiting
- Sponsor
- Mount Sinai Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of carbetocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Proportion of parturients requiring additional uterotonic agents intraoperatively at 90 minutes. Started Jan 2025; status: recruiting.
02
Drugs
carbetocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on NCT06333340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333340.